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1. Introduction 
IgA nephropathy (IgAN), is the most common primary glomerulonephritis worldwide. On 
light microscopy the picture can vary from slight mesangial hypertrophy to extra capillary 
proliferation of glomeruli, with sclerosis and interstitial fibrosis. On immunofluorescence 
staining of kidney sections the disease is characterized by mesangial deposits of IgA, 
predominantly polymeric IgA (pIgA) of the IgA1 subclass, and often co-deposition of 
complement factor C3, properdin and IgG. It is important however to realize that, although 
IgA mesangial deposits are necessary for the diagnosis of IgAN, the latter is not obligatory 
in every individual with mesangial IgA deposits. Thus, IgA deposits may also be seen in 
subjects with no evidence of renal disease [Suzuki et al, 2003; Waldherr et al, 1989] at an 
incidence that ranges from 3 to 16 percent. Furthermore, there are also a number of reports 
documenting IgA deposition in other forms of glomerulonephritis, particularly thin 
basement membrane disease, lupus nephritis, minimal change disease, and diabetic 
nephropathy, a finding which is most probably casual rather than causal. 
IgAN occurs at any age, but most commonly the age of onset is in the second or third 
decade of life. Males are more often affected than females, with a male:female ratio of  2:1. 
Most patients with IgAN present microscopic hematuria with or without mild proteinuria. 
About 40% of patients have episodes of macroscopic hematuria. This is sometimes preceded 
by infections, most commonly upper respiratory tract infections, a phenomenon known as 
“synpharyngitic” hematuria. Other infections like gastrointestinal or urinary tract infections 
have also been reported to precede macroscopic hematuria. Proteinuria is common and can 
vary from mild proteinuria to nephrotic syndrome.  
IgAN has been considered a benign disease for a long time, but nowadays it is clear that 30-
40% of patients may develop renal failure with significant socioeconomical consequenses. In 
Western Europe and the United States of America 7-10% of the patients on renal 
replacement therapy suffer from IgAN. The severity of histological lesions, especially 
diffuse proliferative glomerulonephritis, marked capsular adhesions, fibrocellular crescents, 
glomerular hyalinosis and severe sclerosis, as well as tubulointerstitial damage correlate 
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with poor renal outcome [Schena, 1998]. Next to the gravity of histological lesions, 
unfavourable outcome is associated with persistent hematuria and proteinuria of more than 
1g/day, decreased glomerular filtration rate (GFR) at the time of the diagnosis, and 
hypertension. Although several laboratory tests have been reported to correlate with clinical 
outcome, so far no reliable biomarker has been identified to predict outcome in IgAN. 
Recurrence of IgAN after renal transplantation is common. This finding, along with the 
observation that IgA depositions disappear from a kidney of an IgAN patient, after 
transplantation of this kidney to a non IgAN patient, are suggestive of a rather systemic 
disease.  
2. Genetics of IgAN 
The strongest evidence for the existence of genetic factors in the development and/or 
progression of IgAN comes from descriptions of familial IgAN, largely in white populations 
[Julian et al, 1985], and recent studies suggest that familial and sporadic IgAN may share a 
common pathogenic mechanism and similar outcomes [Izzi et al, 2006]. Τhe genetic 
predisposition may be independent of environmental factors and may reflect an inherited 
susceptibility to develop mesangial glomerulonephritis.  
IgAN does not exhibit classic single-gene Mendelian inheritance pattern [Frimat & Kessler, 
2002]. The complex genetic pattern of IgAN is reflected by the multiple pathways involved 
in its immunopathogenesis, namely multiple discrete immunologic abnormalities related to 
the abnormal overproduction and release of mucosal pIgA1 in the systemic compartment 
and possibly other protein functional abnormalities related to a propensity for mesangial 
deposition of pIgA1. It is therefore probable that the disease-associated genetic variations at 
identified IGAN loci, instead of occuring in the form of “classic” nonsense/missense/splice 
site mutations and deletions/insertions that affect protein structure and function, may be 
rather of the type specific single-nucleotide polymorphism (SNP) alleles in non-coding 
regions or synonymous SNPs in coding regions. The latter function as cis-acting elements 
that alter the transcriptional activity of a disease gene and/or messenger RNA stability and, 
therefore, the expression level of the encoded protein. It is interesting that recent studies 
indicate that 30% to 50% of human genes with coding SNPs can present allelic variation in 
gene expression [Hoogendoorn et al, 2003; Lo et al, 2003]. From this point of view, the most 
comprehensive theory is that several genetic loci contribute significantly to the disease 
susceptibility that underlie the primary immunologic defects observed in IgAN. Each locus 
may occur at a different prevalence rate in different racial/ethnic groups. Variations at these 
major genetic loci may not be sufficient for the development and progression of IgAN and 
the contribution from a potentially large number of modifying genes with modest genetic 
effects but high prevalence is probably needed as well. The various allelic combinations of 
these loci may underlie the different disease phenotypes (disease development and 
progression, nephritic vs. nephrotic clinical presentation, histopathologic subclass, severity 
of disease, responsiveness of proteinuria to angiotensin-converting enzyme [ACE] inhibitors 
and/or angiotensin II receptor blockers [ARBs], etc.) observed in IgAN.  For diseases with 
complex genetic pattern, it has been shown that the optimal analysis approach is the 
combination of linkage, association and sequence approaches. Until now, two basic 
approaches have been used in genetic studies of IgAN: a) genome-wide linkage analysis 
study, a methodology that has been used successfully to identify major 
disease/susceptibility loci, b) candidate-gene association study, mainly used to identify 
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altered genes with modest genetic effects but high prevalence. Recently, a genome-wide 
association study was carried out in cohorts of Chinese and European IgAN patients 
(A.G.Gharawi et al, 2011). Five loci (3 in the major histocompatibility complex at 
chromosome 6p21, a common deletion of CGHR1 and CFHR3 at chromosome 1q32 and one 
locus at chromosome 22q12) were identified. They explain 4-7% of the disease variance. 
2.1 Genome-wide linkage analysis studies 
Genome-wide linkage analysis is used successfully to identify major disease/susceptibility 
genes but has limited power to detect genes of modest effect. Linkage studies involve 
recruitment of families with multiple affected individuals. In a typical whole-genome 
linkage scan, up to 400 microsatellites, or equivalently approximately 10,000 SNP markers, 
equally spaced across the genome, are typed in families to interrogate marker cosegregation 
with a disease phenotype. The advantage of genome-wide linkage studies is that they do not 
require a priori assumption about disease pathogenesis. These studies are very sensitive to 
phenotype misspecification, however their power is limited to detecting rare genetic 
variants with a relatively large effect on the risk of disease.  
Linkage studies of IgAN are faced with multiple challenges. Familial forms of IgAN are 
frequently underrecognized because the associated urinary abnormalities in affected family 
members are often mild or intermittent. Moreover, once familial disease is documented, 
systematic screening by renal biopsy cannot be justified among asymptomatic at-risk 
relatives, necessitating reliance on less accurate phenotypes, such as microscopic hematuria, 
to diagnose affection. Additionally, IgAN has been observed to co-occur in families with 
thin basement membrane disease (TBMD), an autosomal dominant disease caused by 
heterozygous mutations in the collagen type IV genes (COL4A3/COL4A4) [Frasca et al, 
2004]. Short of kidney biopsy or direct sequencing of the very large collagen genes, TBMD 
cannot be reliably excluded among relatives of IgAN patients. Finally, because urinary 
abnormalities may manifest intermittently, one also cannot unequivocally classify at-risk 
relatives as unaffected, necessitating affected-only linkage analysis. The inability to classify 
affected and unaffected individuals accurately is commonly encountered in linkage studies 
of complex traits, leading to decreased study power. Increasing sample size by including 
additional families is also not necessarily helpful in these situations because the diagnosis of 
IgAN likely encompasses several disease subsets, such that expansion to larger sample size 
can paradoxically reduce analytic power due to increased heterogeneity [Durner et al, 1992; 
Cavalli-Sforza & King, 1986].  
To date, four genome-wide linkage studies of familial IgAN have been reported [Gharavi et 
al, 2000; Bisceglia et al, 2006; Paterson et al, 2007, Feehally et al, 2010]. Families in these 
studies have all been ascertained via at least two cases with biopsy-documented IgAN, with 
additional family members diagnosed as affected based on clinical evidence (renal failure or 
multiple documentation of hematuria/proteinuria). In the first study, 30 families with two 
or more affected members were examined [Gharavi et al, 2000]; multipoint linkage analysis 
under the assumption of genetic heterogeneity yielded a peak LOD score of 5.6 on 
chromosome 6q22-23 (locus named IGAN1), with 60% of families linked. The remainder of 
families linked to chromosome 3p24-23 with a suggestive LOD of 2.8. This study 
demonstrated that IgAN is genetically heterogeneous but argued for the existence of a single 
locus with a major effect in some families. In the second genome-wide linkage study 22 
Italian IgAN families were enrolled [Bisceglia et al, 2006] (see section 2.3). The third linkage 
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scan was based on a unique large pedigree with 14 affected relatives (two individuals with 
biopsy defined diagnosis and 12 with hematuria/proteinuria on urine dipstick) [Paterson et 
al, 2007]. Linkage to chromosome 2q36 was detected with a maximal multipoint LOD score 
of 3.47. Most reported linkage intervals did not contain obvious candidate genes, but the 
2q36 locus encompasses the COL4A3 and COL4A4 genes, which are mutated in TBMD. 
Together with the high penetrance of hematuria, this finding suggests that affected 
individuals in the 2q36-linked family may belong to an IgAN subtype that overlaps with 
TBMD. Finally, the fourth genome-wide analysis, carried out in a cohort of IgAN patients 
selected from the UK Glomerulonephritis DNA Bank, the region of the MHC (major 
histocompatibility complex). The strongest association signal included a combination of DQ 
loci and HLA-B. This study suggests that HLA region contains some alleles that predispose 
to the disease in the UK population. In conclusion, four genome-wide linkage studies, 
carried out in four different IgAN patient populations, demonstrate different chromosomal 
traits linked to the disease. 
None of the genes underlying these linkage loci has been identified until now. The 
underlying reasons are numerous, including the phenotyping difficulties discussed above; 
the presence of locus heterogeneity, which limits the ability to precisely map the disease 
interval and find additional linked families to refine loci; the contribution from non-coding 
susceptibility alleles (e.g. point mutations or structural genomic variants within intronic or 
promoter regions), which usually escape detection if mutational screening is confined to 
exonic regions. It is expected that the availability of inexpensive Next-Gen sequencing will 
enable comprehensive interrogation of linkage intervals, facilitating identification of 
disease-risk alleles.  
In addition, future studies of this kind that aim at dissection of increasingly genetically 
homogeneous cohorts must consider the importance of defining distinct clinical subtypes of 
IgAN that may exist within the single pathologic ascertainment criterion currently used to 
diagnose IgAN: light microscopic evidence of mesangial deposits of IgA by 
immunofluorescence. As with all family-based genetic studies, there is a high degree of 
dependency on access to sufficient numbers of clinically well-phenotyped and genetically 
informative cohorts. To address the paucity of cohorts with biopsy-proven IgAN available 
for the conduct of linkage-based, association-based, and sequence-based approaches, the 
European IgAN consortium has published the details of its IgAN Biobank resource [Schena 
et al, 2005]. 
2.2 Candidate-gene association studies 
Candidate-gene association studies examine polymorphisms in only specific genes that are 
selected based on a priori assumption about their involvement in the disease pathogenesis, 
and they are highly sensitive to population stratification, multiple testing, and reporting 
bias. As a result, most candidate-gene association studies in the literature have not been 
replicated [Ioannidis et al, 2001; Hsu SI et al, 2000; Hsu SI, 2001; Frimat & Kessler, 2002], an 
issue which questions the validity and the methodology used in these studies [Hsu & 
Feehally, 2008]. Not surprisingly, candidate-gene studies for IgAN have also been largely 
unrevealing. Many candidate genes have been proposed, but for most of them no solid a 
priori evidence for their involvement in IgAN existed, whereas most were studied in the 
context of IgAN progression rather than causality. Over the last 15 years, there were more 
than 120 candidate-gene association studies for IgAN published in the English literature and 
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indexed on PubMed (e.g., components of the renin-angiotensin-aldosterone pathway, 
mediators of inflammation and/or vascular tone, components of the mesangial matrix, and 
various receptors for polymeric IgA1 expressed in mesangial cells) [Kiryluk et al, 2010]. Of 
these, 39 (31%) studies examined genetic polymorphisms in association with susceptibility 
to IgAN, 40 (32%) examined an association with disease severity, progression, or 
complications, and 44 (35%) examined both susceptibility and risk of progression. Many 
candidate-gene association studies are lacking in functional genetics. 
Approximately one third of all studies involved polymorphisms in the renin-angiotensin-
aldosterone system (RAAS). A widely studied example of the dilemma of repeated non-
replication of results is represented by genetic case-control association studies of the 
angiotensin I–converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism in the 
development and/or progression of IgAN, as well as a whole host of common human 
diseases and conditions, including cardiovascular disease, complications of diabetes such as 
retinopathy and nephropathy, glomerular, tubulointerstitial, and renal cystic renal diseases, 
and even renal allograft survival [Hsu SI et al, 2000; Hsu SI, 2001; Schena et al, 2001]. The 
interest in studying the ACE I/D polymorphism is based on evidence for “biologic 
plausibility.” Rigat and colleagues reported in 1990 that the ACE I/D polymorphism in 
intron 16 of the human ACE gene accounts for half of the variation in serum ACE levels in a 
white study cohort [Rigat et al, 1990], and this is due to the presence of a transcriptional 
repressor element in the I allele [Hunley et al, 1996]. 
There have been numerous population-based studies that either support or refute an 
association between the D allele and progression of renal disease in these conditions [Hsu SI 
et al, 2000; Hsu SI, 2001]. Recent meta-analyses have concluded that the D allele is not 
associated with renal disease progression in patients with IgAN or diabetic nephropathy 
[Schena et al, 2001; Kunz et al, 1998]. Despite more than a dozen generally small genetic 
case-control studies of the ACE I/D polymorphism in both white and Asian IgAN cohorts 
have been done, no definite conclusions can be drawn from them regarding the association 
between the D allele or DD genotype and development and/or progression of IgAN. 
Population-based genetic association studies of other genes encoding proteins in the RAAS 
such as angiotensinogen (AGT) and the angiotensin II type 1 receptor (ATR1), as well as 
renin (REN) and aldosterone synthase (CYP11b2), have also generated conflicting results, as 
have similar studies of the “expanded” RAAS that includes 11b-hydroxysteroid 
dehydrogenase type 2 (11bHSD2) and the mineralocorticoid receptor (MLR) [Poch E et al, 
2001]. In general, the approach has been to genotype a single common polymorphism in 
each gene with the use of polymerase chain reaction/restriction fragment length 
polymorphism (PCR-RFLP). It is remarkable that to date, the role of the RAAS, whose 
components ACE and ATR1 are the targets of ACE inhibitors and angiotensin-II receptor 
blockers (ARB), respectively, has not been convincingly demonstrated by any genetic 
association study. 
In general, most of these studies were of poor quality and severely underpowered and, 
therefore, negative findings were almost universally inconclusive. Overall, the average size 
of case–control cohorts per study was 182 cases and 171 controls. Many studies used ad hoc 
controls derived from unscreened blood donors who were poorly matched to the cases in 
terms of ancestry and geography. The potential impact of confounding by population 
stratification was ignored by the majority of studies, despite the fact that the tools for 
quantification of this problem have been developed. An additional matter of concern is the 
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lack of adequate correction (permutation testing) for multiple, non-independent tests which 
would be anticipated as long as several of these studies tested several hypotheses (multiple 
polymorphisms, multiple phenotypes, or multiple genetic models). Other major problems 
included inadequate or variable SNP coverage of candidate genomic areas, with several 
studies examining only a single polymorphism. Thus far, only one group attempted to 
survey the entire genome, yet the results have not been replicated, are inconclusive and 
difficult to interpret, as long as an underpowered cohort was studied with inadequate 
coverage of ~80,000 SNPs [Obara et al, 2003; Ohtsubo et al, 2005]. Moreover, 77% of all 
published candidate-gene studies reported positive findings, an observation that is likely 
explained by a combination of high rate of false positives and a strong publication bias, 
whereas the statistical effect of the study of the same patient cohorts for multiple 
polymorphisms has never been accounted for in the literature [Kiryluk et al, 2010]. Most 
findings were not reproduced in other populations. None of the above problems is unique 
to the field of IgAN and for these reasons, new general guidelines aimed at improving the 
design and execution of genetic association studies have recently been formulated [von Elm 
et al, 2007; Little et al, 2009]. 
In the post-genomic era, there has been a renewed interest in conducting genetic association 
studies, especially SNP-based, whole-genome association studies, to identify genetic 
variations associated with the development and/or progression of a number of common 
human diseases. This renewed interest reflects the important finding that linkage 
disequilibrium (LD), the phenomenon that particular alleles at nearby sites can co-occur on 
the same haplotype more often than expected by chance [Goldstein, 2001; Wahl et al, 2003] 
is highly structured into discrete blocks separated by hotspots for recombination. The 
haplotype block model for LD has important implications for the way in which genetic 
association studies should now be conducted, and may explain at least in part the problem 
of repeated non-replication of results that has plagued such studies in the past. Based on the 
haplotype block model of LD, the ACE I/D polymorphism is a single marker variant in the 
ACE gene, whereas in unknown yet whether the D allele defines a simple population of 
subjects at risk for disease or not. The lumping of subgroups defined by haplotypes that 
share the D allele may explain at least in part the basis for discrepant reports of genetic 
association with disease. 
Nowadays the common SNP haplotype block model is considered essential for the 
credibility of a study [Couser, 2003] and genetic association studies, especially family based, 
that employ one or more methodologically valid approaches and satisfy the minimum 
rigorous conditions for a reliable genetic association study are viewed as studies with solid 
documentation. These include mainly studies employing biologic plausibility, haplotype 
relative risk analysis to identify statistically significant “at-risk haplotype[s]” associated 
with small P values, use of family-based methodologies, such as the transmission 
equilibrium test (TDT/sib-TDT) or the family-based association test (FBAT) to directly study 
trios/sib-trios and extended families or to verify the absence of significant population 
stratification bias (admixture) inherent in population-based case-control association studies, 
and the study of moderately large i.e., adequately powered] cohorts. To date, very few 
studies examining candidate genes have employed the family-based TDT study 
methodology and/or analysis of “at-risk” haplotypes, reflecting the emergence of the first 
studies to attempt to satisfy minimum criteria for a valid association study.  
A family- and haplotype-based association study employing the TDT methodology has 
shown that 2093C and 2180T SNP variants in the 3’-untranslated region of the Megsin gene 
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were significantly more frequently transmitted from heterozygous parents to patients than 
expected in the extended TDT analysis (increased co-transmission in 232 Chinese families,  
P < 0.001). In addition, haplotype relative risk (HRR) analyses showed that these same SNP 
alleles were more often transmitted to patients (HRR = 1.568, P < 0.014 for the 2093C allele; 
HRR = 2.114, P < 0.001 for the 2180T allele) [Li YJ et al, 2004]. The same group using a 
similar approach recently reported that the Megsin 23167G SNP variant is associated with 
both susceptibility and progression of IgAN in 435 Chinese patients and their family 
members using TDT and HRR analyses [Takei et al, 2006]. The GG genotype was found to 
be associated with severe histologic lesions and disease progression. Megsin is a member of 
the serpin (serine proteinase inhibitor) superfamily that is upregulated in the context of 
mesangial proliferation and extracellular matrix expansion in IgAN, and therefore 
represents a strong candidate gene for susceptibility to IgAN. Lately, the gene encoding 
Cosmc, a C1Gal-T1 chaperone protein which also mediates IgA O-galactosylation was 
studied as a candidate gene involved in the pathogenesis of IgAN but no evidence for a role 
for Cosmc mutations was reported [Malycha et al, 2009].  
2.3 IgAN consortium 
The IgAN Biobank, coordinated by F.P. Schena, contains at minimum 72 multiplex 
extended pedigrees, 159 trios, and 1,068 cases and 1,040 matched controls. All subjects 
enrolled are white and belong to various geographic areas from Germany, Italy, and 
Greece [Schena et al, 2005]. Aiming at a genome wide linkage study, which has been 
considered the most promising approach to identify IgAN susceptibility genes, a group of 
investigators constituted the European IgAN Consortium which was initially funded by 
the European Union. DNA samples of IgAN patients and relatives belonging to 74 
multiple extended pedigrees were collected. Moreover, 166 trios (affected sons or 
daughters and their healthy parents), 1,085 patients with biopsy-proven IgAN and 1,125 
healthy subjects were included in the Biobank. In combination with linkage analysis, 
family based candidate gene association studies were also applied in an efford to discover 
responsible genes and overcome obstacles inherent the genetic analysis of complex traits 
such as IgAN.  
Linkage Analysis Studies – The European IgAN Consortium performed the first genome-wide 
scan involving 22 Italian multiplex IgAN families [Bisceglia L et al, 2006]. A total of 186 
individuals (59 affected and 127 unaffected) were genotyped and included in a two-stage 
linkage analysis. The regions 4q26–31 and 17q12–22 exhibited the strongest evidence of 
linkage by non-parametric analysis (best p values of 0.0025 and 0.0045, respectively). These 
localizations were also supported by multipoint parametric analysis where a peak LOD 
score of 1.83 (ǂ=0.50) and of 2.56 (ǂ=0.65), respectively, were obtained using the affected 
only dominant model, and by allowing for the presence of genetic heterogeneity. These 
regions became the second (IGAN2) and third (IGAN3) genetic locus candidates to contain 
causative and/or susceptibility genes for familial IgAN. Other regions did not reach the 
threshold of a suggestive or significant LOD score; however, the enrolment of additional 
IgAN families means that these chromosomal regions may be explored in the near future. 
The above results provide further evidence for genetic heterogeneity among IgAN families. 
Evidence of linkage to multiple chromosomal regions is consistent with both an 
oligo/polygenic and a multiple susceptibility gene model for familial IgAN with 
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small/moderate effects in determining the pathological phenotype. The analysis of the 
known genes located in these two novel loci (positional information procedure), carried out 
consulting the National Center for Biotechnology Information, identified some potential 
candidate genes such as the transient receptor potential channel 3 (TRPC3) gene, the 
interleukin-2 (IL-2) gene, and the IL-21 gene located in 4q26–31, which could be largely 
involved in the unbalanced Th1/Th2 immune response reported in IgAN patients. In 
addition, the histone deacetylase 5 (HD5) gene and the granulin (GRN) gene located on the 
17q12–22 region, which could be involved in the immune-response deregulation, will also 
considered. Family-based association studies, evaluating the distribution of these candidate 
gene polymorphisms, are in progress.  
Microarray Studies – Different high-throughput gene analysis techniques can be used for 
obtaining transcriptome profiling of renal diseases. Microarray analysis represents the best 
and the latest approach to gain information on global gene expression. Genome-wide 
linkage analyses have identified at least three locus candidates containing IgAN 
susceptibility genes, although no specific gene(s) have been discovered. Microarrays are 
now in use to fingerprint the pathological process. 
A published study postulated that changes in gene expression patterns in circulating 
leukocytes of IgAN patients may correlate with renal disease activity [Preston et al, 2004]. 
The investigators identified 14 upregulated genes. The BTG2, NCUBE1, FLJ2948, SRPK1, 
LYZ, GIG2 and IL-8 genes correlated with serum creatinine levels and the PMAIP1, SRPK1, 
SSI-3, LYZ and PTGS2 genes correlated with higher values of creatinine clearance, thus 
implying that the latter group of genes may provide a protective effect, while the 
overexpression of other genes such as B3GNT5, AXUD1 and GIG-2 indicated a worse 
prognosis. This gene signature reflected kidney function and did not correlate with 
hematuria or proteinuria. The authors concluded that studies carried out on large 
populations of IgAN patients will be necessary to confirm that the leukocyte gene 
expression profile can be used as a marker for diagnosis and for predicting outcome. The 
European IgAN Consortium has recently organized a protocol for studying gene expression 
in peripheral blood mononuclear cells (PBMC) and their subpopulations from IgAN patients 
with different clinical and histological patterns. Cox et al [2010] conducted a whole-genome 
expression study to identify genes and pathways differently modulated in peripheral blood 
leukocytes of IgAN patients. Gene expression of leukocytes demonstrated the hyperactivity 
of two important pathways as the canonical WNT- catenin and the PI3k/Akt pathways. 
The abnormal WNT signalling was also confirmed in IgAN patient’s monocytes and to a 
less extent in B lymphocytes. Low gene expression of inversion and phosphatase and tensin 
homolog (PTEN) are responsible for the hyperactivation of these two pathways that enhance 
cell proliferation through lymphoid enhancer factor-1 (LEF-1) of which the gene is located 
within our previous described region 4q26-31 linked to IgAN [Bisceglia et al, 2006]. Finally, 
the hyperactivation of the PJ3k/Akt pathway is in linkage with the upregulation of the 
immunoproteasome in peripheral blood mononuclear cells of IgAN patients, reported by 
Coppo et al, [2009]. 
Expression profiling using serial analysis of gene expression (SAGE) and microarray 
techniques allows global description of expressed genes present in renal tissue. This is a 
high throughput genomics technology which enables the simultaneous determination of a 
large number of genes from tissue samples. Preston et al identified 13 upregulated genes in 
IgAN renal biopsy samples. The cluster analysis identified 3 clusters with 7, 12 and 1 
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involved gene, respectively [Preston et al, 2004]. The expression levels of these genes were 
then examined on expanded RNA samples from other renal biopsies, leukocyte samples and 
cultured primary cells. Data demonstrated the involvement of the genes GABP and STAT3 
in cluster I, and gp330 (megalin), MBP45K, MEF2, Oct1 and GABX in cluster II. The use of 
laser-capture microdissection applied to renal biopsy samples in combination with 
differential gene expression analysis is expected to provide novel knowledge in the search 
for IgAN candidate genes. 
Candidate genes association studies – The IgAN Consortium takes care of the collection of 
biological samples from large homogeneous cohorts of IgAN patients, their parents and 
their first degree relatives, and family-based association studies are preferred to analyze the 
role of some candidate genes. A family-based association study, including 53 patients, 45 
complete trios, 4 incomplete trios and 36 discordant siblings, evaluated the impact of some 
Th1/Th2/Th3/TR-type lymphocyte and monocyte/macrophage cytokines on IgAN 
susceptibility [Schena FP et al, 2006]. Cytokine gene polymorphisms with a potential 
regulatory role on their production were investigated using the family-based association test 
(FBAT): IFN intron-1 CA-repeat at position 1349–1373; IL-13 –1055C/T; TGF 915G/C; IL-
10 5’-proximal and distal microsatellites; TNF –308G/A, –238G/A. The FBAT multi-allelic 
analysis showed an association between IFN polymorphism and susceptibility to IgAN 
(p=0.03). The bi-allelic analysis showed that the 13-CA repeat allele was preferentially 
transmitted to the affected individuals (p=0.006; Bonferroni p=0.04). The direct sequencing 
of IFN amplicons showed a strict association between the 13-CA repeat allele and the A 
variant of the +874T/A SNP (rs2430561) directly adjacent to the 5’ end of the microsatellite. 
The in vitro production of IFN evaluated in PBMC from 10 genotyped patients 
demonstrated a correlation between the +874A allele and a lower production of IFNǄ 
(p=0.028). Notably, the +874A variant was associated with transcriptional downregulation 
of INFǄ gene promoter activity, consistent with the known role of NF-κB in the 
transcriptional regulation of the INFǄ gene. 
The occurrence of the +874A variant is responsible for the low production of IFNǄ and 
predisposes to a preferential Th2-mediated immune response. The predominance of this 
variant in individuals with IgAN may be responsible for the onset of the disease. This 
unbalanced Th2 cytokine production in response to upper respiratory tract infections may 
be a significant pathogenic factor in human IgAN. The prevalence of Th2 cytokines may 
also explain the abnormality in IgA1 glycosylation occurring in IgAN patients and the 
concomitant formation of circulating IgA1-IgG immune complexes. Hyperfunction of Th2 
cells and cytokine polarity are linked to a more nephritogenic pattern of IgA1 
glycosylation in the animal model, and the decreased glycosylation of IgA1 elicited by 
Th2 cytokines is blunted in vitro by the addition of IFNǄ [Ebihara et al, 2008]. The core 1 
ǃ1,3-galactosyltransferase (C1Gal-T1) is suspected to be involved in the abnormal 
glycosylation process of IgA1 in IgAN. With the genetic characterization of the enzymes 
responsible for O-glycosylation of IgA1, it has been possible to study changes in the O-
glycosylation of IgA1 at a genetic level. Most recently two groups [Pirulli et al, 2009; Li GS 
et al, 2007] have independently found that SNPs in the C1Gal-T1 gene are associated with 
a genetic susceptibility to IgAN in Chinese and Italian populations, albeit it is not clear 
how these polymorphisms relate to changes in the functional activity of C1Gal-T1. The 
C1Gal-T1 gene complete sequence analysis was performed in 284 IgAN patients and 234 
healthy controls. A statistically significant association of the genotype 1365G/G with 
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susceptibility to IgAN (χ2=17.58, p<0.0001, odds ratio 2.57 [95% CI: 1.64–4.04]), but not 
with the progression of the disease, was found [Pirulli et al, 2009]. The latter case-control 
association study demonstrates that the low expression of C1Gal-T1 seems to confer 
susceptibility to IgAN. 
In conclusion, to date the Consortium has identified two loci (located on chromosomes 
4q26–31 and 17q12–22), in addition to a previous study which described the first IgAN locus 
on chromosome 6q22–23. The functional mapping of genes involved in the disease proceeds 
from the identification of susceptibility loci identified by linkage analysis (step 1) to the 
isolation of candidate genes within gene disease-susceptibility loci, after obtaining 
information by microarray analysis carried out on peripheral leukocytes and renal tissue 
samples (step 2). Next steps will be the design of RNA interference agents against selected 
genes (step 3) and the application of systematically tested effect of RNA agents on functional 
cellular assay (step 4). The above combined high-throughput technologies will give 
information on the pathogenic mechanisms of IgAN. In addition, these data may indicate 
potential targets for screening, prevention and early diagnosis of the disease and more 
appropriate and effective treatment. 
3. Treatment of IgAN   
Treatment strategy for IgAN remains a controversial issue, even more as published 
randomized controlled trials (RCTs) on this topic are few and most studies are 
underpowered to provide definitive information. Furthermore, the disease heterogeneity, its 
clinical course along with the slow rate of GFR decline (1 to 3 mL/min per year) seen in 
many patients hinders the ability to perform adequate studies. An additional obstacle is the 
fact that a significant percentage of the patients have only minimal clinical presentation, 
such as isolated microhematuria, no or minimal proteinuria and normal GFR, and are often 
not biopsied or even identified. Still no treatment is known to modify mesangial deposition 
of IgA, which obviously reflects our incomplete knowledge of immunopathogenesis of 
IgAN [Barratt et al, 2007], and available treatment options are directed mostly at 
downstream immune and inflammatory events that may lead on to renal scarring. 
Therefore, as more pathogenetic details, the genetic substrate and heterogeneity of IgAN 
become increasingly understood, novel treatment strategies with solid therapeutic targets 
are anticipated, as long as the traditional therapies used until today seem symptomatic 
rather than etiologic. The discovery and establishment of novel biomarkers associated with 
the disease activity and outcome will provide the prognostic and therapeutic tool for more 
accurate and clear therapeutic targeting.  
However, there seems to be a consensus regarding patient selection for the different 
therapeutic approaches. Patient selection for therapy is based in part upon the perceived 
risk of progressive kidney disease: 
 Patients with isolated hematuria, no or minimal proteinuria (<500mg/day), a normal 
GFR and no signs of progressive disease, such as increasing proteinuria, blood pressure, 
and/or serum creatinine, are typically not treated. 
 Patients with persistent proteinuria (>500 mg/day), normal or only slightly reduced 
GFR (>50mL/min) that is not declining rapidly, and only mild to moderate histologic 
findings on renal biopsy are managed with general interventions to slow progression 
with ACE-inhibitors or angiotensin receptor blockers (ARB) or with combination 
therapy of corticosteroid (6 months) and ACE-inhibitors forever.   
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 Patients with more severe or rapidly progressive disease (eg, proteinuria > 1g or 
proteinuria persisting despite ACE inhibitor/ARB therapy, rising serum creatinine, 
and/or renal biopsy with more severe histologic findings, but no significant chronic 
changes) may benefit from immunosuppressive therapy in addition to non-
immunosuppressive interventions to slow disease progression.  
 In the future, the Oxford histologic classification system, once validated, is anticipated 
to become a useful prognostic tool that could lead in the future our therapeutic choices 
[Working Group of the International IgAN Network and the Renal Pathology Society, 
2010].  
3.1 Monitoring disease activity 
Up to date, there are no specific markers to identify continued immunologic activity. 
Instead, the clinical parameters typically used as the main therapeutic criterion are the urine 
sediment, protein excretion and the serum creatinine concentration. Persistent hematuria is 
generally a marker of persistent immunologic activity, but not necessarily of progressive 
disease. This finding may be a sign of a "smoldering" segmental necrotizing lesion, 
suggestive of "capillaritis." Hematuria alone does not require any form of therapy. 
Proteinuria, rather than hematuria alone, is a marker of more severe disease [Donadio et al, 
2002]. Increasing proteinuria may be due to one of two factors: ongoing active disease; and 
secondary glomerular injury due to non-immunologic progression. It is often not possible to 
distinguish between these two possibilities, except for a rapid increase in protein excretion 
which is only seen with active disease. Protein excretion most often falls with ACE 
inhibitor/ARB therapy and the degree of proteinuria is, as described below, one of the end 
points of such therapy. Protein excretion also may fall spontaneously, particularly during 
recovery from an acute episode and perhaps in children, and following effective 
immunosuppressive therapy. Finally, serum creatinine, unless it is rapidly rising, permits an 
estimation of the GFR. As noted above, most patients with chronic IgAN have stable or 
slowly progressive disease. The rate of GFR decline is often as low as 1 to 3 mL/min per 
year, a change that will not detectably raise the serum creatinine above normal levels for 
many years [Rekola et al, 1991]. Thus, a stable and even normal serum creatinine does not 
necessarily indicate stable disease. 
The establishment of accurate biomarkers is necessary for the optimal categorization and 
treatment of patients with IgAN. Over the last few years specific urine biomolecules have 
been proposed as probable biomarkers to be used in the prognosis and therapeutic strategy 
in patients with IgAN. Two recent studies identified urine epidermal growth factor and 
monocyte chemoattractant protein-1 as strong independent predictors of renal outcome in 
patients with IgAN [Torres et al, 2008; Stangou et al, 2009]. These and other biomolecules 
are being validated as probable biomarkers of IgAN in studies underway. 
3.2 Non-immunosuppressive therapies 
Three main non-immunosuppressive therapies are in use in IgAN [Barratt & Feehally, 2006; 
Appel & Waldman, 2006]: 
 ACE inhibitors or ARB, to control blood pressure and to slow down progression of the 
renal disease. 
 Statin therapy, for lipid-lowering in selected patients, to lower cardiovascular risk and 
possibly reduce disease progression. 
 Fish oil (omega-3 fatty acids) may also be beneficial in certain cases.  
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3.2.1 Angiotensin inhibition 
The progression of IgAN may be slowed by anti-hypertensive and anti-proteinuric therapy 
that can minimize secondary glomerular injury [Kanno et al, 2000]. The treatment goals with 
angiotensin inhibition are the same as those in other forms of proteinuric chronic kidney 
disease as described in the K/DOQI guidelines [K/DOQI, 2004]. ACE inhibitors and ARBs 
act by reducing the intraglomerular pressure and by directly improving the size-selective 
properties of the glomerular capillary wall, both of which contribute to reducing protein 
excretion [Remuzzi et al, 1991; Maschio et al, 1994]. 
Both observational studies [Cattran et al, 1994; Kanno et al, 2005] and small randomized 
trials [Maschio et al, 1994; Praga et al, 2003; Li PK et al, 2006] have provided suggestive 
evidence that ACE inhibitors or ARBs are more effective than other antihypertensive drugs 
in slowing the progressive decline in GFR in IgAN as they are in other forms of chronic 
proteinuric kidney disease. Praga et al in their randomized trial in 44 IgAN patients with 
proteinuria (≥0.5 g/day, mean 1.9 g/day) and a serum creatinine concentration ≤1.5 mg/dL 
at baseline, found a significant decrease in proteinuria in the enalapril group (1.9 g/day at 
baseline to 0.9 g/day at the last visit) and a significantly higher renal survival, defined as 
less than a 50 percent increase in the serum creatinine concentration, at 6 years of follow up 
[Praga et al, 2003]. More recently, Li et al in their double-blind randomized placebo-
controlled HKVIN trial in 109 Chinese patients with protein excretion ≥1 g/day (mean ~2.0 
g/day), found a better renal survival, defined as doubling of serum creatinine or ESRD, a 
significant improvement in proteinuria (33 % reduction in proteinuria) and a slower rate of 
decline in GFR (4.6 versus 6.9 mL/min per year) in the valsartan group compared to placebo 
[Li PK et al, 2006]. Similarly, the IgACE trial in 65 young patients with moderate proteinuria 
(between 1 and 3.5 grams/day per 1.73 m2) and creatinine clearance >50 mL/min per  
1.73 m2 revealed a better renal survival (fewer patients with >30% decline in renal function) 
and significant improvement in proteinuria at 38 months of follow-up in the benazepril 
group compared to the placebo group [Coppo, 2007].  
Normotensive patients who excrete less than 500 mg of protein per day are not typically 
treated with angiotensin inhibition. However, because most patients progress slowly over 
time, monitoring of the serum creatinine and protein excretion at yearly intervals is 
recommended. Angiotensin inhibition should be started if there is evidence of progressive 
disease and protein excretion above 500 mg/day. 
The addition of an ARB to an ACE inhibitor in patients with IgAN seems to exert a further 
antiproteinuric effect [Russo et al, 1999, 2001], albeit there are no randomized trials 
showing that this regimen improves renal outcomes. This finding is consistent with meta-
analyses of trials in different glomerular diseases, the largest of which found a significant 
18 to 25% greater reduction in proteinuria with combined ACE inhibitors and ARBs 
compared to monotherapy [Kunz et al, 2008; Catapano et al, 2008]. The rationale for this 
combination therapy is the assumption that ARBs would counteract theAT1-mediated 
effect of residual angiotensin II formation by non-ACE enzymes like chymase, whereas 
ACE inhibitors would additionally increase the level of kinins. Furthermore, ACE 
inhibitors as well as ARBs would synergistically elevate the levels of angiotensin, which 
also might promote vasodilation. Finally, combining both drug classes might simply 
provide a higher degree of blockade of the classic renin-angiotensin system pathways 
[Alexopoulos, 2004].  However, any anticipated benefits from this combination should be 
weighted against possible adverse effects in individual patients; this is important 
especially given the findings from the ONTARGET trial in 25,620 patients with vascular 
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disease or diabetes, where an increase in adverse side effects (including a possible 
increase in mortality) in patients who received combination therapy with an ACE 
inhibitor and ARB was shown, compared to those who received monotherapy 
[ONTARGET Investigators, 2008; Mann et al, 2008].  
3.2.2 Lipid-lowering therapy 
Chronic kidney disease is associated with a marked increase in cardiovascular risk, and is 
now considered a coronary artery disease risk equivalent. Furthermore, lipid-lowering with 
statins has been associated with a slower rate of loss of GFR in patients in some patients 
with mild to moderate CKD, and there are indications for such a beneficial effect of statins 
in patients with IgAN as well [Kano et al, 2003]. Therefore, it seems rational that all patients 
with decreased kidney function and/or hypercholesterolemia should receive lipid-lowering 
therapy with a statin, with treatment goals similar to that in patients with underlying 
coronary heart disease.  
3.2.3 Fish oil 
The rationale for using fish oil (omega-3 fatty acids) in IgAN is based on the premise that 
they may limit the production or action of cytokines and eicosanoids evoked by the initial or 
by repeated immunologic renal injury, and the resulting production of mediators involved 
in renal damage [Donadio, 1991]. Randomized controlled trials evaluating fish oil in patients 
with IgAN have reported conflicting results [Donadio et al, 1994; Alexopoulos et al, 2004; 
Donadio et al, 1999, 2001; Bennett et al, 1989; Pettersson et al, 1994; Hogg et al, 2006; Ferraro 
et al, 2009]. In the largest and most well documented and conducted randomized trial in 106 
patients with baseline creatinine clearance 80 mL/min and protein excretion of 2.5 to  
3 g/day, Donadio et al found better patient and renal outcomes at 4 years, extended also at 
>6 years, in patients having received 12g of fish oil for 2 years, compared to patients having 
received a similar amount of olive oil [Donadio et al, 1994, 1999]. Similarly, in a controlled 
study of 14 IgAN patients and 14 controls, a low dose of fish oil (0.85 g eicosapentaenoic 
acid and 0.57 g phytohemaglutinin) was found effective in slowing renal progression in 
high-risk patients with IgAN and particularly those with advanced renal disease 
[Alexopoulos et al, 2004]. On the other hand, in the randomized controlled trial by the 
Southwest Pediatric Nephrology Study Group in 96 patients with IgAN, mean GFR >100 
mL/min per 1.73 m2 and proteinuria 1.4 to 2.2 g/day, no significant benefit in the renal 
outcome was found in patients assigned to omega-3 fatty acids (4 g/day) for two years 
compared to the patients assigned to either alternate day prednisone or placebo [Hogg et al, 
2006]. On the basis of the existing data, fish oil can be tried in addition to ACE inhibitors or 
ARBs in patients with protein excretion >500 to 1000 mg/day, a gradual reduction in GFR, 
and mild to moderate histologic lesions [Alexopoulos E, 2004]. 
3.3 Immunosuppressive therapy 
The optimal role of immunosuppressive therapy in IgAN is uncertain [Barratt & Feehally, 
2006; Appel & Waldman, 2006]. A variety of regimens have been used, mostly consisting of 
corticosteroids alone or with other immunosuppressive drugs. The available studies are not 
conclusive since most are relatively small and have limited follow-up, and the results are 
sometimes conflicting [D'Amico, 1992; Alamartine et al, 1991; Alexopoulos, 2004; Strippoli et 
al, 2003; Laville & Alamartine, 2004; Ballardie, 2004; Julian, 2000; Dillon, 2001]. There is 
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rather consensus that mild, stable, or very slowly progressive IgAN should not be treated 
with corticosteroids or other immunosuppressive therapies, given the limited evidence of 
benefit and their known toxicity from chronic use [Floege & Eitner, 2005; Locatelli et al, 
1999]. Corticosteroid or other immunosuppressive therapy should only be attempted in 
patients with clinical and histologic evidence of active inflammation (eg, hematuria and/or 
proliferative or necrotizing glomerular changes). Patients with chronic kidney disease with 
significant tubulointerstitial fibrosis and glomerulosclerosis are not likely to benefit from 
such therapy and are likely to be harmed from the side effects.  
3.3.1 Corticosteroids 
Current evidence regarding the potential benefit of corticosteroid therapy in IgAN are 
rather limited, as long as most of the studies performed are uncontrolled retrospective 
observations; moreover, the few available randomized controlled trials are rather small and 
in most of them the standard recommendations for proteinuria and blood pressure goals 
were not followed, limiting thus the applicability of the findings to current practice.  
Whatsoever, these studies point towards a beneficial effect of corticosteroid therapy 
(administered for 6 up to >24 months) in proteinuria and perhaps in renal survival [Floege 
& Eitner, 2005; Nolin & Courteau, 1999; Kobayashi Y et al, 1989, 1996; Pozzi et al, 1999, 2004; 
Tamoura et al, 2001; Katafuchi et al, 2003; Hotta et al, 2001; Moriyama et al, 2004; Lv et al, 
2009, Manno et al, 2009], probably preferentially in individuals with preserved kidney 
function (eg, creatinine clearance above 50 mL/min) [Kobayashi et al, 1989, 1996; Pozzi et al, 
1999, 2004].  Two randomised clinical trials demonstrated the benefit of the combination 
therapy with corticosteroids and ACE inhibitors on long-term follow-up in proteinuric 
IgAN patients. Lv et al (2009) evaluated the efficacy of the combination therapy versus ACE-
inhibitors alone in a small number of IgAN patients with mild or moderate histologic lesions 
and with a follow-up period that was too short to evaluate the renal survival. Data 
demonstrated that the combination therapy reduced better the urinary protein excretion 
than the administration of ACE-inhibitors alone.  
Even more, Manno et al enrolled 97 IgAN patients with moderate histologic lesion (see 
IgAN classification of F.P. Schena in Manno et al., 2007) daily proteinuria more than 1.0g 
and estimated GFR more than 50 ml/min/1.73m2. Patients were randomly allocated to 
receive a 6-month course of oral prednisone plus ramipril or ramipril alone for the total 
duration of the follow-up (96 months). The combination of corticosteroids and ramipril 
provided less probability of renal disease progression because induced the decline of GFR 
and daily proteinuria. In an interesting recent meta-analysis of randomized and quasi-
randomized controlled trials of corticosteroid treatment in IgAN against treatment without 
steroids, Zhou et al found that steroid therapy, especially long-term, is associated with a 
significant benefit in proteinuria and renal survival [Zhou et al, 2011].  
In addition, the IgAN patients seemingly to benefit from prednisone therapy are those with 
nephrotic syndrome, little or no hematuria, preserved kidney function, minimal glomerular 
changes on light microscopy, and diffuse fusion of glomerular epithelial cell foot processes 
on electron microscopy. These histologic findings are characteristic of minimal change 
disease, and these patients behave accordingly, frequently developing a remission with 
corticosteroids and occasionally requiring cytotoxics for frequently relapsing proteinuria 
[Mustonen et al, 1983; Lai KN et al, 1986; Cheng et al, 1989]. Mesangial IgA deposits in these 
patients often disappear or are greatly reduced following steroid-induced remission [Cheng 
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et al, 1989].  Nephrotic syndrome can also occur with severe chronic IgAN and relatively 
advanced disease on renal biopsy. These patients do not seem to benefit from corticosteroid 
therapy alone [Mustonen et al, 1983; Lai KN et al, 1986]. 
3.3.2 Combined immunosuppressive therapy  
Combined immunosuppressive therapy should only be attempted in patients with more 
severe active disease as defined by a more rapidly progressive clinical course and/or 
histologic evidence of severe active inflammation (eg, crescent formation). Early therapy is 
important because improvement is rare when the baseline serum creatinine concentration is 
greater than 3.0 mg/dL in the absence of crescentic glomerulonephritis [Alexopoulos E, 
2004].  
Corticosteroids plus azathioprine — Whether the addition of azathioprine provide any benefit 
to that of corticosteroids is still debatable. In a multicenter randomized trial by Pozzi et al in 
207 patients with plasma creatinine ≤ 2.0 mg/dL and protein excretion >1.0 g/day, at a 
median follow-up of 4.9 years, there was no difference neither in renal survival time, 
defined as the time to 50% increase in plasma creatinine from baseline, nor in the decrease in 
proteinuria between patients who received corticosteroids alone or along with azathioprine 
(1.5 mg/kg /day for six months) [Pozzi et al, 2010]. However, in the above study, only a 
rather small percentage of patients were receiving either ACE inhibitors or ARBs, and even 
fewer patients were receiving statins. Most recently, Stangou et al published a randomized, 
yet underpowered study in 22 patients with IgAN and eGRF≥30mL/min, urine protein 
≥1g/day, blood pressure <130/80mmHg, who failed to respond to previous treatment with 
renin-angiotensin system inhibitors and poly-unsaturated fatty acids administered for at 
least 6 months. During the 5th year after the diagnosis was made, the patients were 
randomized to receive either methylprednisolone alone, or methyl-prednisolone in 
combination with azathioprine, for 12months, while treatment with renin-angiotensin 
system inhibitors and poly-unsaturated fatty acids continued unchanged in both groups. 
Both, steroid treatment alone, or steroids in combination with azathioprine were found to be 
equally effective in reducing the severity of proteinuria and stabilizing renal function 
[Stangou et al, 2011].  
Corticosteroids plus cyclophosphamide— There are evidence suggesting that patients with 
severe or progressive disease (eg, rising creatinine, nephrotic range proteinuria, and/or 
marked proliferation without crescents) who do not have significant chronic damage on 
kidney biopsy may benefit from combined immunosuppressive therapy with 
prednisone and cyclophosphamide. This regimen was evaluated in a study of Ballardie et al 
in 38 patients with IgAN and initially impaired renal function (baseline serum creatinine 
between 1.5 and 2.8 mg/dL, mean baseline protein excretion 4.0 to 4.5 g/day, no crescents 
on biopsy) that was declining at a relatively moderate rate (by at least 15% per year). 
Compared with the control group, the patients treated with combination therapy 
(prednisolone 40mg/day tapered to 10mg/day by two years plus low-dose 
cyclophosphamide for 3 months followed by low-dose azathioprine for at least 2 years) had 
a significant reduction in protein excretion during the first six months of therapy that 
persisted during follow-up (eg, reached 1.8 g/day in treatment group versus unchanged at 
4.4 g/day in controls at one year). Renal survival was significantly higher in the treatment 
group at two (82 versus 68 percent) and five years (72 versus 6 percent). [Ballardie et al, 
2002]. 
www.intechopen.com
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
84
Uncontrolled reports in patients with crescentic, rapidly progressive glomerulonephritis 
suggest possible benefit from regimens similar to those used in idiopathic crescentic 
glomerulonephritis: intravenous pulse methylprednisolone followed by oral prednisone, 
intravenous or oral cyclophosphamide, and/or plasmapheresis [Welch et al, 1988; Lai KN et 
al, 1987a; Rocatello et al, 1995; McIntyre et al, 2001; Tumlin et al, 2003]. Corticosteroids may 
act in this setting by diminishing acute inflammatory injury rather than by correcting the 
abnormality in IgA production [Galla, 1995]. In a study by Rocatello et al, although a 
substantial clinical improvement was found with the administration of aggressive 
combination therapy (including pulse methylprednisolone, oral cyclophosphamide, and 
plasmapheresis) for 2 months in six patients with crescentic glomerulonephritis due to IgAN 
[Rocatello et al, 1995], yet cellular crescents failed to remit in repeat renal biopsy, whereas 
the disease continued to progress in half of the patients after therapy was discontinued. 
Limited data for a more prolonged course of aggressive immunosuppressive therapy (pulse 
methylprednisolone 15mg/kg/day for 3 days, followed by oral prednisolone 1 mg/kg/ day 
for 60 days gradually tapered, along with monthly iv cyclophosphamide (0.5 g/m2) for 6 
months) point towards a significant improvement in the serum creatinine and in protein 
excretion along with a significant reversion of cellular crescents and endocapillary 
proliferation [Tumlin et al, 2003].  
These limited data suggest that patients with active crescentic glomerulonephritis who do 
not have significant chronic damage on kidney biopsy may benefit from therapy that 
initially includes intravenous cyclophosphamide. This is consistent with the benefit noted 
with a similar regimen in other forms of crescentic glomerulonephritis.  
3.3.3 Other immunosuppressive agents 
Cyclosporine — Cyclosporine has been investigated in small studies, and resulted in reduced 
proteinuria. In a recent study, Shin et al reported a significant benefit of cyclosporine 
therapy in proteinuria reduction and renal pathology regression in 14 children with IgAN 
and near normal creatinine clearance [Shin et al, 2010]. However, there are important issues 
of concern regarding its use in IgAN treatment, with most important the associated 
nephrotoxicity, which can lead to harmful effects on renal function [Lai KN et al, 1987b; 
Cattran, 1991], as well as the rapid disease relapse after drug discontinuation. 
Mycophenolate mofetil — Small, prospective placebo-controlled randomized trials of 
mycophenolate mofetil (MMF) in which the patients were also treated with ACE inhibitors, 
have produced conflicting results, ranging from no benefit [Maes et al, 2004; Frisch et al, 
2005] to a reduction in proteinuria and decrease in rate of decline of GFR [Tang et al, 2010]. 
A short course (< 6 months) of MMF in patients with persistent proteinuria (>1.5 g/day) and 
well-maintained renal function (serum creatinine <1.5 mg/dL) in addition to ACE 
inhibitor/ARB therapy may be considered in patients with well-preserved renal histology 
on biopsy. Current evidence does not support the use of MMF in patients with advanced 
disease (serum creatinine >2.5 to 3 mg/dL) [Cattran & Appel, 2011]. 
3.4 Other possible interventions 
Tonsillectomy — Several retrospective studies have suggested that tonsillectomy, usually in 
combination with some immunosuppressive therapy, is associated with improved renal 
survival among patients with relatively mild renal injury [Hotta et al, 2001; Xie et al, 2003; 
Komatsu et al, 2008]. These non-randomized studies provide some evidence that 
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tonsillectomy may be effective in inducing remission of proteinuria and hematuria in 
patients with IgAN (ie, proteinuria >500 mg/day). However, there are no randomized trials 
of tonsillectomy in IgAN, the design of the above studies precludes any definitive 
conclusions regarding the overall efficacy of tonsillectomy in IgAN, while other studies 
reported negative results [Rasche et al, 1999].  
Low antigen diet — The rationale for using a low antigen diet in IgAN, ie diet free of gluten, 
dairy products, eggs, and most meats, is that dietary macromolecules may be responsible for 
activating the mucosal IgA system. When given to 21 consecutive patients with IgAN, 
protein excretion fell markedly in all 12 patients whose baseline rate was more than 1g/day. 
In addition, repeat renal biopsy showed significant reductions in mesangial IgA and 
complement deposition and mesangial cellularity [Ferri et al, 1993]. However, the benefits in 
the above study have not been confirmed and a report using a gluten-free diet alone for 
several years was unable to document improvement in either proteinuria or renal function 
despite a reduction in the level of circulating IgA-containing immune complexes [Coppo et 
al, 1990]. 
Intravenous immune globulin — At least part of the rationale for intravenous immune 
globulin (IVIG) therapy in IgAN comes from the observation that a partial IgG deficiency, 
which could be corrected with IVIG, may predispose to infections that trigger flare-ups of 
the renal disease [Rostoker et al, 1989, 1994]. Despite the promising findings from two small 
studies with the administration of high-dose IVIG in severe IgAN, characterized by heavy 
proteinuria and a relatively rapid decline in GFR (reduction in protein excretion, prevention 
of GFR decline, decreased inflammatory activity and IgA deposition on repeat renal biopsy) 
[Rostoker et al, 1994; Rasche et al, 2006], these findings need to be confirmed by larger 
studies.  
4. Conclusion 
Genetic susceptibility for IgAN exhibits a complex genetic pattern. To date  various groups 
and the European IgAN Consortium have identified several loci. The extensive genetic 
studies under way with the use of delicate, high-throughput technologies will give 
information on the pathogenic mechanisms of IgAN. In addition, these data may indicate 
potential targets for screening, prevention and early diagnosis of the disease and more 
appropriate and effective treatment. 
Summarizing the most updated data, following are concise treatment guidelines: 
 Patients with isolated hematuria, no or minimal proteinuria (<0.5g/day), and a normal 
GFR need no treatment. Such patients should be periodically monitored at 6 to 12 
month intervals to assess disease progression that might warrant therapy. 
 Patients with persistent proteinuria (>0.5 or >1 g/day), should be treated with 
angiotensin inhibition (ACE inhibitor or ARB), with a target of a minimum reduction in 
protein excretion of at least 50 to 60% from baseline values and a goal protein excretion 
of <0.5 or <1 g/day.  
 All patients who meet criteria for angiotensin inhibition may also be considered as 
candidates to receive fish oil.  
 Patients with persistent nephrotic syndrome and/or chronic kidney disease who have 
dyslipidemia should be treated with a statin, primarily for cardiovascular protection.  
 Corticosteroid therapy for at least  6 months is indicated in the following cases: 
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a. In patients with acute onset of nephrotic syndrome and minimal changes beyond 
mesangial IgA deposits on renal biopsy (as in patients with minimal change 
disease). 
b. In patients with moderate renal lesions (eg, hematuria with persistent proteinuria 
>1 g/day and/or GFR>50ml/min) in association with ACE inhibitors or ARBs.  
 For patients with severe disease at baseline (defined as initial serum creatinine >1.5 
mg/dL) or progressive disease (eg, increasing serum creatinine and/or protein 
excretion) who do not have significant chronic damage on kidney biopsy, therapy with 
oral prednisone and cyclophosphamide is recommended.  
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twenty four chapters divided conveniently into five sections. The first section deals with primary
glomerulopathies, and the second section is devoted to glomerulopathies complicating infectious conditions.
The third section deals with systemic autoimmune disorders and vasculitides which constitute major causes of
glomerular disease and often renal failure. The fourth section includes chapters discussing the glomerular
involvement in some major metabolic and systemic conditions. The final section has chapters which relate to
some general aspects of glomerular diseases. This book will form an excellent reference tool for practicing and
academic nephrology community.
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